# ZEISS Group account plan

> ZEISS is a foundation-owned German optics and optoelectronics group: €11,896m revenue in FY2024/25 and about 47,400 employees.

## At a glance

ZEISS develops, produces and sells semiconductor lithography optics, industrial metrology, microscopes, medical technology, eyeglass lenses and other optical products, from its headquarters in Oberkochen, Germany. It is represented in around 50 countries with around 40 R&D centres and 30 production sites, and earns 94% of revenue outside Germany. In FY2024/25 (to 30 September 2025) revenue reached a record €11,896m (+9%), EBIT was €1,552m (13% margin) and consolidated profit €952m, with 46,622 employees at year-end and about 47,400 at 31 March 2026. The sole shareholder is the Carl Zeiss Foundation, whose statutes prohibit an IPO; Carl Zeiss Meditec AG is a listed subsidiary in which the group holds a 59.1% capital share.

## Business units

- **Semiconductor Manufacturing Technology (SMT)** (€5,055m FY2024/25 revenue, about 42% of group revenue): Lithography optics, photomask systems and process control solutions for chip makers; ZEISS optics sit in the wafer scanners of strategic partner ASML. Revenue rose 23% in FY2024/25 on DUV and EUV optics and AI-driven demand, and grew another 6% to €2,612m in H1 FY2025/26, although FY2024/25 orders fell 4%. Led by Dr. Frank Rohmund.
- **Medical Technology (MED)** (€2,704m FY2024/25 revenue, about 23% of group revenue): Ophthalmology (cataract, retina and refractive surgery systems and consumables) and Microsurgery (neuro/ENT, spine and dental visualisation), largely through listed Carl Zeiss Meditec AG. Revenue grew 4% in FY2024/25 but fell 7% to €1,187m in H1 FY2025/26; Andreas Pecher runs it on an interim basis since 1 January 2026.
- **Industrial Quality & Research (IQR)** (€2,334m FY2024/25 revenue, about 20% of group revenue): Coordinate measuring machines, optical and multisensory systems, 3D X-ray and software for industry, plus light, electron and X-ray microscopes for research. Revenue fell 1% in FY2024/25 as research microscopy demand dropped in the US and China, and a €225m goodwill impairment was booked; H1 FY2025/26 revenue fell 3% to €1,131m. Led by Dr. Marc Wawerla from 1 October 2025.
- **Consumer Markets (CM)** (€1,569m FY2024/25 revenue, about 13% of group revenue): Vision Care: ZEISS eyeglass lenses, eye-examination devices and services for eye care professionals, with myopia management driving growth in China. Revenue fell 6% in FY2024/25 amid price pressure, then rose 1% to €782m in H1 FY2025/26. Led by Sven Hermann; a new Extended Reality (XRX) unit started on 1 October 2025.
- **Other (incl. Photonics & Optics)** (€234m FY2024/25 revenue, about 2% of group revenue): The Photonics & Optics strategic business unit groups smaller units outside the segments, including Consumer Products transferred from Consumer Markets on 1 October 2024.

## Strategic priorities

- **Competitiveness programme**: Announced in June 2026, it targets annual savings of "several hundred million euros over the next three years" versus FY2024/25 through cost-structure changes in the segments, corporate administration and country organisations; job reductions are expected.
- **ZEISS Agenda 2030**: Succeeds #agenda25 and was presented internally in November 2025, aiming to serve customer needs more quickly and generate sustainable profitable growth.
- **Data- and process-driven organisation**: The transformation started three years ago continues, including the rollout of modern CRM and AI solutions and a Digital Competence Center with more than 1,200 digital experts.
- **ProfitUp at Carl Zeiss Meditec**: More than €200m of annual profit improvement by FY2028/29, with up to 1,000 positions affected, divestment of non-mission-critical products and an adjusted EBITA margin above 15% by FY2028/29.
- **Reducing dependence on SMT**: The CEO names years of declining momentum in the direct-to-market segments and the resulting dependency on SMT as a fundamental challenge; the owners aim for a balanced portfolio.

## Latest results

In H1 FY2025/26 (six months to 31 March 2026) group revenue was €5.841bn, up 1% from €5.794bn, and EBIT rose €33m to €955m. SMT grew 6% to €2,612m after a recent strong upturn in demand, while IQR (-3%) and MED (-7%) declined on a very difficult market and negative currency effects, and Consumer Markets grew 1%. R&D stayed at 14% of revenue and the equity ratio at 51%. ZEISS expects no improvement in the second half and is preparing for further revenue decline in the direct-to-market segments; the FY2025/26 outlook calls for a slightly lower revenue level and an EBIT margin of around 11%.

## Investments and deals

- **EUV capacity and Jena site**: Capex on property, plant and equipment was €1,294m in FY2024/25, notably for next-generation EUV production and the new high-tech site in Jena (about 3,500 employees).
- **Beyond Gravity Lithography acquisition**: Acquired Beyond Gravity's Lithography division for €99.4m, effective 29 November 2024, adding actuator and mechatronic production and R&D capacity.
- **Brighten Optix acquisition**: Agreed on 4 June 2025 to acquire Taiwan's largest rigid contact lens maker (about 180 employees, €24m revenue in 2024), for orthokeratology lenses.
- **R&D spending**: €1,731m of R&D expensed in FY2024/25 (15% of revenue), with 7,364 R&D staff and about 13,000 patents.
- **Financing**: A €900m promissory note loan placed on 29 October 2024 and a €200m syndicated loan on 29 September 2025, plus an undrawn €1,300m revolving facility.

## Challenges and risks

- **Concentration on semiconductors**: SMT made about 42% of FY2024/25 revenue and depends on ASML and chip makers' capex; without it the group would have reported stagnation.
- **Weak direct-to-market segments**: IQR, MED and CM face lower research budgets, price pressure, new Chinese competitors and falling order volumes; FY2024/25 orders of €11,315m were below revenue.
- **Inefficient structures**: The CEO says structures built during the growth years are no longer efficient in all areas; Vision Care in Aalen cuts 180 full-time jobs by the end of 2026 and the Aalen-Ebnat metrology campus is on hold.
- **Geopolitics and trade**: Tariffs, protectionism and export restrictions in the technology sector and for rare raw materials, plus strong negative currency effects.
- **Medical technology setbacks**: Carl Zeiss Meditec's H1 FY2025/26 revenue fell 5.7% to €991m, hit by weaker IOL sales in China after a licence revocation, and a goodwill write-down that may exceed €100m is possible.

## What leadership says

> "We are acting from a position of strength before the circumstances force us to act." — Andreas Pecher, President and CEO, ZEISS half-year figures press release, 9 June 2026

> "after years of strong growth, it is especially important now to optimize cost structures so that we continue to generate the funds for future investments." — Stefan Müller, CFO, ZEISS half-year figures press release, 9 June 2026

> "Our innovation arm is strong. However, our commercial arm remains underdeveloped in many markets." — Andreas Pecher, interim CEO of Carl Zeiss Meditec AG, Carl Zeiss Meditec H1 2025/26 earnings call, 12 May 2026

> "sustained, substantial investment in digitalization and in research and development is the foundation for further growth achieved through technological differentiation and innovation, even in a challenging environment." — Dr. Michael Bolle, Supervisory Board chair, ZEISS Group Annual Report 2024/25, 18 December 2025


## Where a supplier can help

- **Cost-structure and shared-services efficiency**: Tied to the competitiveness programme's savings target in administration and country organisations: process automation, outsourcing and procurement-optimisation providers fit the plan.
- **CRM, SAP and commercial excellence**: Tied to ProfitUp's reinvestment in SAP and a group-wide CRM and to the stated underdeveloped commercial arm: CRM implementation, sales-enablement and data partners are directly relevant.
- **Semiconductor capacity build-out**: Tied to the EUV capex and the Jena site: suppliers of precision components, clean-room infrastructure and manufacturing automation can support SMT capacity.
- **Localisation and best-cost sourcing**: Tied to Meditec's plan to move manufacturing and selected R&D to China and best-cost countries and to optimise supply chains: contract manufacturers and supply-chain advisers fit.
- **AI and data in the transformation**: Tied to the data- and process-driven organisation priority: AI, data-platform and analytics vendors can support the group-wide transformation.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [ZEISS Group Annual Report 2024/25](https://asset-downloads.zeiss.com/catalogs/download/cco2/c026d158-e8ca-4cbe-ac7f-8ef3541ed925/ZEISS_Gruppe_Gescha_ftsbericht_2024-25_EN_826455_0.pdf)

Annual report · 2025-12-18

- ZEISS is a foundation-owned optics and optoelectronics group (sole shareholder: the Carl Zeiss Foundation, whose statutes prohibit an IPO), headquartered in Oberkochen, Germany, with 46,622 employees at 30 Sep 2025 and four segments: Semiconductor Manufacturing Technology (SMT), Industrial Quality & Research (IQR), Medical Technology (MED) and Consumer Markets (CM).
- FY2024/25 (to 30 Sep 2025): record revenue of €11,896m (+9%, +10% currency-adjusted), EBIT €1,552m (13% margin, unchanged), EBITDA €2,472m, consolidated profit €952m (down from €1,031m on a 36% tax rate driven by €240m of non-deductible goodwill impairments, €225m of them in IQR). 94% of revenue is earned outside Germany.
- Growth came almost entirely from SMT: revenue passed €5bn for the first time (€5,055m, +23%) on EUV/DUV lithography optics for strategic partner ASML; IQR fell 1% to €2,334m, MED rose 4% to €2,704m, CM fell 6% to €1,569m.
- Incoming orders of €11,315m were flat and below revenue; SMT orders fell 4% as customers grew cautious and pushed hard on cost.
- R&D: €1,731m expensed (15% of revenue; €1,954m before grants and capitalisation), 7,364 R&D staff, about 13,000 patents; capex on property, plant and equipment €1,294m (prior year €1,620m), notably for next-generation EUV production and the new high-tech site in Jena.
- Balance sheet: total assets €18,329m, equity ratio 48%, net liquidity minus €263m after a €900m promissory note loan and a €200m syndicated loan; operating cash flow €1,814m.
- Strategy: #agenda25 is succeeded by the ZEISS Agenda 2030 (presented internally in November 2025); a transformation into a "data- and process-driven organization" continues; a new Extended Reality (XRX) strategic business unit started on 1 October 2025; Brighten Optix (Taiwan, orthokeratology lenses) is being acquired.
- Leadership churn: Andreas Pecher (former head of SMT) became President and CEO on 1 April 2025; Dr. Frank Rohmund now leads SMT, Dr. Marc Wawerla IQR (from 1 Oct 2025); MED head Maximilian Foerst left on 31 Dec 2025 over an admitted compliance violation and Pecher runs MED on an interim basis.
- Outlook FY2025/26: a slightly lower revenue level, EBIT margin of around 11%, positive free cash flow in the low triple-digit million range, a slightly higher R&D ratio and a less dynamic headcount; the CEO warns the outlook is "significantly more challenging".

### [ZEISS Group half-year figures 2025/26 (press release, 9 June 2026)](https://www.zeiss.com/corporate/en/about-zeiss/present/newsroom/press-releases/2026/half-year-figures.html)

Interim report · 2026-06-09

- H1 FY2025/26 (six months to 31 March 2026): ZEISS Group revenue €5.841bn, up 1% (prior year €5.794bn); EBIT €955m, up €33m; about 47,400 employees.
- Segment revenue: Semiconductor Manufacturing Technology €2,612m (+6%, +7% currency-adjusted), Industrial Quality & Research €1,131m (-3%, +2%), Medical Technology €1,187m (-7%, -1%), Consumer Markets €782m (+1%, +6%).
- SMT grew again after "initially volatile conditions in the semiconductor market and a recent strong upturn in demand"; the three direct-to-market segments faced a very difficult market and strong negative currency effects. EMEA grew.
- R&D 14% of revenue (€0.8bn); equity €9.5bn (51% equity ratio); PP&E investment €0.4bn.
- CEO Andreas Pecher names two fundamental challenges: years of declining momentum in the direct-to-market segments, creating strong dependency on SMT, and structures from the growth years "that are no longer efficient in all areas".
- Outlook: no improvement expected in H2; ZEISS must "prepare for further revenue decline in the direct-to-market segments".
- A group-wide competitiveness programme targets annual savings of "several hundred million euros over the next three years" versus FY2024/25, through cost-structure changes in the segments, corporate administration and country organisations; job reductions are expected, while above-average investment in innovation and markets continues.

### [Zeiss im 'unsicheren Marktumfeld' - CEO Andreas Pecher at the annual press conference (Schwäbische Zeitung)](https://www.schwaebische.de/wirtschaft/zeiss-wird-vorsichtiger-was-das-fuer-die-standorte-auf-der-ostalb-heisst-4203788)

Executive talk · Andreas Pecher, President and CEO, Carl Zeiss AG · 2025-12-19

- Regional business daily's account (19 Dec 2025) of the ZEISS annual press conference, with CEO Andreas Pecher's statements and his answers to the paper's questions; quotes below are translated from German.
- Pecher expects the uncertain market environment to continue in FY2025/26 and, in the worst case, to show up as a revenue decline; for the first time in years orders (€11.3bn) were below revenue (€11.9bn) in FY2024/25. He called the group's growth "solid" (translation).
- Semiconductors dominate: more than 40% of revenue comes from optics for ASML lithography systems (€5.1bn, +23%); without SMT the group would have reported stagnation. Pecher said the owners also aim for a balanced portfolio.
- Capacity adjustments: all divisions must be competitive; where business is weak and conditions will not improve, capacity will be cut, first by "soft measures" (translation; working-time accounts, short-time work), and jobs may go where a problem is structural. Vision Care in Aalen cuts 180 full-time jobs by the end of 2026.
- The planned metrology campus in Aalen-Ebnat (2,500 jobs) has been on hold since April 2025 and its original size is in question.
- AI-driven chip capacity build-out drives SMT; ZEISS, ASML and Trumpf hold a 100% share of EUV and High-NA EUV scanners. Pecher views spreading protectionism "with scepticism and concern" (translation) and says ZEISS sees no competitor emerging yet in China.
- German staff (nearly 23,000) receive a €2,700 profit-sharing bonus.

### [Carl Zeiss Meditec H1 2025/26 earnings call transcript (12 May 2026)](https://www.zeiss.com/content/dam/med-ag/investor-relations/financial-calendar/conference-calls/afx_transcript_conference-call_6m202526.pdf)

Executive talk · Andreas Pecher, President and CEO of the ZEISS Group and interim CEO of Carl Zeiss Meditec AG · 2026-05-12

- Carl Zeiss Meditec AG (the listed ZEISS subsidiary at the core of the group's Medical Technology segment) H1 FY2025/26 call, 12 May 2026, led by Andreas Pecher as interim CEO (also ZEISS Group CEO) with CFO Justus Wehmer.
- H1 revenue €991m (-5.7%; -2.8% at constant currency; FX effects €46m); orders €1.038bn (-5.2%); adjusted EBITA €60.5m, margin 6.1% vs 10.7%; reported EBITA margin 3.9%.
- Causes: currency, weaker intraocular lens (IOL) sales in China after a bifocal IOL licence revocation, and a €13m write-off on the deprioritised Infinite Vision Optics (IVO) project. Ophthalmology revenue €754m (-6.7%), EBITA margin 1.5%; Microsurgery €237m (-2.1%, +1.8% currency-adjusted), margin 11.5%.
- Regions: Americas 25% of revenue (-11%), EMEA 35% (+5.6% currency-adjusted), APAC 40% with China 21% (-10%).
- "ProfitUp": more than €200m of annual profit improvement by FY2028/29, up to 1,000 positions affected worldwide, divestment or phase-out of non-mission-critical products, manufacturing and selected R&D moved to China and best-cost countries, a stronger commercial organisation; about €40m reinvested in infrastructure (SAP, a ZEISS Group-wide CRM, new Jena HQ, pricier group shared services), one-offs up to €150m.
- Guidance FY2025/26: revenue €2.15-2.2bn, adjusted EBITA margin 8-10%; a goodwill write-down that may exceed €100m (linked to the 2018 IanTECH acquisition) is possible. Mid-term: at least mid-single-digit organic growth and adjusted EBITA margin above 15% by FY2028/29; 16-20% still seen as viable long term.
- Pecher: a CEO successor should be named by fiscal year-end; the new CEO must not "give up" on the programme.

## Questions about ZEISS Group

### What does ZEISS do?

ZEISS is an optics and optoelectronics group that makes semiconductor lithography optics for ASML, industrial metrology, microscopes, medical technology and eyeglass lenses, organised in four segments: SMT, IQR, MED and Consumer Markets.

### What is ZEISS's revenue?

Revenue was a record €11,896m in FY2024/25 (to 30 September 2025), up 9%, with EBIT of €1,552m. In H1 FY2025/26 revenue was €5.841bn, up 1%.

### How many employees does ZEISS have?

About 47,400 people worldwide at 31 March 2026, against 46,622 at 30 September 2025.

### Who leads ZEISS?

Andreas Pecher has been President and CEO since 1 April 2025, with Stefan Müller as CFO. The group is wholly owned by the Carl Zeiss Foundation.

### What is ZEISS's strategy?

The ZEISS Agenda 2030 and a group-wide competitiveness programme targeting annual savings of several hundred million euros over three years, while continuing above-average investment in innovation.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
